Skip to content
lifestyle.duovoltart.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AlzeCure Pharma
Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026
June 29, 2026
Positive Results From The Phase Ib Clinical Study of NeuroRestore ACD856, Under Development for Alzheimer’s
June 16, 2026
AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer’s Project
June 9, 2026
Notice To Annual General Meeting in AlzeCure Pharma AB
May 26, 2026
New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain
May 6, 2026
AlzeCure Publishes its Interim Report for January – March 2026
May 5, 2026
Adjusted Timeline for the Previously Communicated Rights Issue
April 30, 2026
AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million
April 26, 2026
AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million
April 26, 2026
Last Patient has Completed AlzeCure’s Phase Ib Clinical Study with NeuroRestore ACD856
April 20, 2026
←
Previous Page
1
2
3
Next Page
→